Drug Database
FA

Factor VIIIa (LongAte)

✓ Approved

PolyTherics Limited · F8 · Recombinant Proteins

What is Factor VIIIa?

Factor VIIIa is a recombinant proteins developed by PolyTherics Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesLongAte
CompanyPolyTherics Limited
Drug ClassRecombinant Proteins, Cell-based Therapies
Molecular TargetF8
RouteInjectable (Others), Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, PolyTherics Limited

Mechanism of Action

Molecular Targets

Factor VIIIa acts on 1 molecular target:

F8coagulation factor VIII (AHF, FVIII)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

Factor VIIIa is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersFactor VIII deficiency✓ Approved

Related Research Articles

PubMedAdvances in therapy2026-05-24

Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight.

Kanu Chisom C, Karn Hayley H, Clucas Claudine C, Goetz Iris I et al.

Individuals with obesity or overweight experience a substantial socioemotional burden and lower quality of life. Existing patient-reported outcome (PRO) instruments do not adequately measure emotional functioning concepts important to individuals with obesity/overweight. This study describes the psychometric properties of the Weight and Emotions Scale (WES), a new PRO measure to evaluate emotional functioning in adults with obesity or overweight. 120 adults completed two web-based surveys (baseline, week 2). Survey 1 comprised the 16-item WES, Control of Eating Questionnaire, Impact of Weight on Quality of Life-Lite Clinical Trials Version, Impact of Weight on Self-Perceptions Questionnaire, and Patient Global Impression of Severity (PGIS) 'Overall Emotional Impact of Weight.' Survey 2 included the WES and PGIS 'Overall Emotional Impact of Weight.' Factor structure, reliability, and validity of the WES were assessed. Exploratory factor analysis of the WES supported a two-factor structure as items loaded strongly (≥ 0.59) on factors corresponding to positive and negative feelings. The unidimensional framework was revised to include two WES domains ('Positive Feelings' [8 items] and 'Negative Feelings' [8 items]). The WES domain and total scores demonstrated excellent internal consistency (Cronbach's alpha ≥ 0.90) and good test-retest reliability (intraclass correlation coefficient: 0.87-0.89). Convergent validity of the WES was demonstrated via large correlations with the Impact of Weight on Quality of Life-Lite Clinical Trials Version 'Psychosocial' score and items, Impact of Weight on Self-Perceptions Questionnaire total score, and PGIS 'Overall Emotional Impact of Weight.' Known-groups validity was demonstrated via higher WES domain and total scores in participants who reported feeling good about their weight (PGIS 'Overall Emotional Impact of Weight'). The final version of the WES with 16 items is a reliable and valid PRO measure for assessing emotional functioning in individuals with obesity or overweight, with potential utility in observational studies, clinical trials, and clinical practice.

PMID 42176180
Read full article →
PubMedEuropean journal of pharmacology2026-05-24

Sulfonated peptide alleviates hypertensive renal injury via antioxidant, anti-inflammatory, and renal metabolomics.

Li Yuexiu Y, Song Siyi S, Lin Qianxia Q, Jin Huoxi H

Excessive dietary salt intake is a well-established risk factor for hypertension, with numerous underscoring its significant role in the pathogenesis of cardiovascular diseases. Dietary management is widely recognized as essential for both the prevention and treatment of hypertension. This study aimed to evaluate the preventive efficacy of a sulfonated peptide, Leucyl-glycyl-asparaginyl-glycyl-cysteinylsulfonic acid-proline (Leu-Gly-Asn-Gly-Cya-Pro, SLP), against high-salt-induced hypertension and renal injury, thereby providing new insights into hypertension prevention strategies. Compared with the unsulfonated peptide, Leucyl-glycyl- asparaginyl-glycyl-cysteinyl-proline (Leu-Gly-Asn-Gly-Cys-Pro, LP), SLP was more effective in attenuating the elevation of blood pressure, inhibiting renal fibrosis, improving markers of renal injury (alpha-1-microglobulin and uric acid), and reducing levels of inflammatory factors and adhesion molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and interleukin-1β). Additionally, SLP upregulated endothelial nitric oxide synthase while downregulating inducible nitric oxide synthase in the kidney. Similarly, high levels of nuclear factor-kappa B and phosphorylated nuclear factor-kappa B induced by high-salt in the kidney were effectively prevented by SLP treatment. Furthermore, SLP exerted antihypertensive effects through the regulation of tryptophan, purine, glycerophospholipid, and cysteine metabolism, as well as the citrate cycle. Overall, sulfonation modification enhances the anti-inflammatory and metabolic regulatory activities of peptides, with the sulfonated peptides SLP significantly preventing high-salt-induced hypertension and its associated renal complications.

PMID 42176725
Read full article →
PubMedExperimental eye research2026-05-24

Targeting H3K27me3 Methyltransferase EZH2 Restrains ANGPT2 Signaling in Choroidal Neovascularization.

Ho Sok I SI, Li Lin L, Zuo Sipeng S, Tang Jieling J et al.

Aberrant histone-modifying activity drives pathological angiogenesis, yet the epigenetic regulators that govern choroidal neovascularization (CNV) remain poorly defined. Here we demonstrate that the histone methyltransferase enhancer of zeste homolog 2 (EZH2) and its catalytic product H3K27me3 are markedly elevated in human and mouse CNV lesions. Vascular endothelial growth factor (VEGF) rapidly induced EZH2 expression in endothelial cells (ECs). Pharmacologic inhibition of EZH2 with 3-deazaneplanocin A (DZNep) suppressed VEGF-driven EC proliferation, migration, and tube formation in vitro and reduced laser-induced CNV volume by 41.9% in vivo (P<0.01). RNA-seq revealed that EZH2 inhibition down-regulates a transcriptional program enriched for mitotic cell-cycle genes, microtubule cytoskeleton organizers, and pro-angiogenic cytokines. Conversely, the flow-dependent transcription factor Krüppel-like factor 2 (KLF2) emerged as one of the most significantly up-regulated genes following EZH2 blockade. Chromatin immunoprecipitation confirmed loss of H3K27me3 at the KLF2 promoter, leading to derepression of KLF2 and subsequent suppression of angiopoietin-2 (ANGPT2), a key permissive factor for pathological angiogenesis. Rescue experiments showed that siRNA-mediated knockdown of KLF2 reversed the anti-angiogenic effects of DZNep, validating the EZH2-KLF2-ANGPT2 axis as a functionally critical pathway. Collectively, our findings identify EZH2 as an essential epigenetic driver of CNV and provide pre-clinical evidence that EZH2 inhibition constitutes a promising therapeutic strategy for neovascular ocular diseases.

PMID 42176839
Read full article →
PubMedNeurochemistry international2026-05-24

Neuro-Nutraceutical Role Of Indian Spices, Spice Mixes And Their Bio-Actives: An update.

Vismaya, Rajini P S PS

Neurodegenerative disorders (NDD), one of the major health care challenges, are exponentially increasing as the elderly segment of the population continues growing in size worldwide. Currently, the role of nutraceuticals, in general and particularly for brain health, has generated immense research interest. Ancient, traditionally used culinary spices have been recognized for their potential health benefits. Abundant evidence clearly suggests that spices do impart considerable biological activity in the central nervous system (CNS). Owing to the multi-mechanistic actions of spices/bioactives, scientific interest is resurgent in characterizing, understanding, and exploring their neuro-nutraceutical role. The current review summarizes experimental evidence on the nutraceutical attributes of a subset of Indian spices. Major molecular mechanisms by which these compounds counteract neuropathology- such as antioxidant activity, anti-inflammatory effects, modulation of signaling pathways (e.g., Nrf2, NF-κB, MAPK), enhancement of synaptic plasticity, and stimulation of neurogenesis are discussed. The neuroprotective efficacy of Spice extract/bioactives as therapeutics is dependent on bioavailability, pharmacokinetics, and delivery challenges that prevent adequate concentrations from reaching the brain. However, the development of several nano-formulations for various spice bioactives has significantly addressed these issues. Further, the data limitations, potential obstacles to be overcome, and current research on metabolic engineering and the nanotechnology of spice bioactives are also presented. Although the randomized controlled trials (RCTs) in humans are limited, and restricted to a few spice bio-actives, abundant evidence in various preclinical models prompts one to hypothesize that Indian spices /bio-actives are quite promising as neuro- nutraceuticals in the management of NDD.

PMID 42176806
Read full article →
PubMedArchives of medical research2026-05-24

Targeted Epigenetic Silencing of Jumonji Domain-Containing Protein 3 Alleviates Nuclear Factor-Kappa B-Mediated Inflammation in Familial Mediterranean Fever.

Eldeen Ghada Nour GN, Sokkar Mona F MF, Lotfy Randa S RS, Zarouk Waheba A WA et al.

Familial Mediterranean fever (FMF) is an inherited autoinflammatory condition caused by variants in the MEFV gene encoding pyrin, the essential component of the NLRP3/NF-κB complex of inflammasomes. Deregulation of nuclear factor-kappa B (NF-κB), a key proinflammatory mediator, leads to chronic inflammation in autoinflammatory/autoimmune diseases. Epigenetic modulation offers a new approach to regulate inflammasome activity, with Jumonji domain-containing protein 3 (JMJD3) being a promising target for managing inflammatory illnesses. GSK-J4 is a selective inhibitor of JMJD3, restricting pro-inflammatory cytokines and inflammation. Our research aimed to elucidate the role of JMJD3 and the NF-κB-JMJD3 signaling pathways in regulating inflammation in an in vitro model, and to investigate GSK-J4's effect in inhibiting inflammasome activation in primed peripheral blood mononuclear cells (PBMCs) isolated from FMF cases. PBMCs were cultured and primed with LPS, and then treated with GSK-J4. JMJD3 knockdown was achieved using siRNA interference. Cellular inflammatory dynamics were assessed by Western blotting (WB) and ELISA. The qRT-PCR was used for gene expression quantification. Untreated cells served as a negative control. Our results showed significantly downregulated gene expression of NF-κB, NLRP3, and inflammatory cytokines in GSK-J4-treated cells compared to untreated cells, as confirmed by ELISA. WB reported a reduction of NF-κB in induced cells following GSK-J4 treatment. Knocking down JMJD3 also showed decreased levels of JMJD3, NF-κB, and inflammatory cytokines, indicating its proinflammatory role. The study showed that selective inhibition or silencing of JMJD3 significantly suppressed the inflammasome in FMF cases, suggesting its role as a therapeutic target for alleviating inflammation in various autoinflammatory diseases.

PMID 42176463
Read full article →
PubMedInternational journal of biological macromolecules2026-05-24

A bio-based flame-retardant coating constructed from sodium alginate and tartaric acid derived from wine grape pomace.

Zhang Wei W, Zhang Xinming X, Zhang Longyang L, Zhang Shiqi S et al.

To enhance the thermal insulation and fire safety performance of 50SiMnVB steel, this study innovatively utilizes winery waste to extract tartaric acid (TA), achieving high-value conversion of waste biomass resources. By constructing a tartaric acid (TA)‑sodium alginate (SA) organic cross-linked network and incorporating aluminum hydroxide (Al(OH)3) as an inorganic flame-retardant filler, an SA/TA/Al(OH)3 composite flame-retardant coating was successfully fabricated on the steel surface, forming a high-performance fireproof and thermal insulation material. The results demonstrate that the SA/TA/Al(OH)3-1 composite exhibits excellent flame retardancy, smoke suppression, and thermal insulation properties, as reflected in the following key metrics: a peak heat release rate (pHRR) of 2.21 kW·m-2, total heat release (THR) of 1.72 MJ·m2, peak smoke production rate (pSPR) of 0.00027 m2·s-1, total smoke production (TSP) of 0.07 m2, the limiting oxygen index (LOI) reaches 47.1%, and a char residue yield of 74%. when exposed to a 1300 °C butane flame, the temperature rise rate on the backside was reduced by 53.74%; the Raman spectroscopy ID/IG value of 0.0654 indicates effective enhancement of the thermal stability of the char layer. After 30 min of heating, the backside temperature was only 162.7 °C, with a thermal conductivity as low as 0.083(W/m-1·k-1). The coating also demonstrates good mechanical properties, with a compressive strength of 14.3 MPa. Utilizing bio-based waste materials, this strategy synergistically enhances flame retardancy, thermal insulation, and eco-friendliness, offering a sustainable pathway for developing high-performance green protective materials.

PMID 42176918
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Factor VIIIa